SCHEMBL7112398

SCHEMBL7112398

Cn1cnc2c1c(=O)nc(N)n2Cc1ccc2ccccc2c1

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
HIF1A Q16665 1/20 0.47
PNP P00491 4/20 0.44
BACE1 P56817 2/20 0.44
MAPK1 P28482 1/20 0.42
TRPA1 O75762 1/20 0.41
VDR P11473 1/20 0.41
TLR7 Q9NYK1 1/20 0.38
FBP1 P09467 2/20 0.38
CYP19A1 P11511 1/20 0.38
FAAH O00519 1/20 0.37
DPP4 P27487 1/20 0.37
FAP Q12884 1/20 0.37
ADORA2A P29274 1/20 0.36
GAA P10253 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7111074 0.87 PNP (0.44) ALDH1A1SMN1; SMN2HIF1APNPBACE1
SCHEMBL7120152 0.84 PNP (0.45) ALDH1A1SMN1; SMN2HIF1APNPBACE1
SCHEMBL7111860 0.81 PNP (0.45) ALDH1A1SMN1; SMN2HIF1APNPMAPK1
SCHEMBL7117280 0.81 PNP (0.45) ALDH1A1SMN1; SMN2HIF1APNPMAPK1
SCHEMBL7113866 0.81 PNP (0.39) ALDH1A1SMN1; SMN2HIF1APNPBACE1
SCHEMBL7110374 0.81 SMN1; SMN2 (0.48) SMN1; SMN2PNPMAPK1ADORA2A
SCHEMBL7113247 0.81 PNP (0.39) ALDH1A1SMN1; SMN2HIF1APNPBACE1
SCHEMBL7118322 0.80 PNP (0.39) ALDH1A1SMN1; SMN2HIF1APNPBACE1
SCHEMBL7118850 0.79 BACE1 (0.49) ALDH1A1SMN1; SMN2HIF1ABACE1MAPK1
SCHEMBL7977483 0.79 CNOT7 (0.46) ALDH1A1SMN1; SMN2HIF1APNPBACE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030186978-A1 Novel telomerase inhibitors PHARMACIA ITALIA, SPA (IT) 2003-10-02 US claimed
US-20030186978-A1 Novel telomerase inhibitors PHARMACIA ITALIA, SPA (IT) 2003-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030186978-A1 Novel telomerase inhibitors TERT, TERF2IP, TERF2 ALDH1A1 2360/4885SMN1; SMN2 2003/4885HIF1A 2399/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.